Macrogenics Inc stock is traded at $2.32, with a volume of 195,578. It is down -0.22% in the last 24 hours and down -37.77% over the past month. Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
Previous Close:
$2.32
Open:
$2.31
24h Volume:
195,578
Relative Volume:
0.25
Market Cap:
$147.47M
Revenue:
$157.08M
Net Income/Loss:
-$70.36M
P/E Ratio:
-
EPS:
-$1.11
Net Cash Flow:
-$71.69M
1W Performance:
+4.28%
1M Performance:
-37.77%
6M Performance:
-34.23%
1Y Performance:
+57.48%
1-Day Range:
$2.27$2.43
1-Week Range:
$2.25$2.49
52-Week Range:
$1.32$5.08
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics IncSector
HealthcareIndustry
BiotechnologyPhone
301-251-5172Address
9704 MEDICAL CENTER DRIVE, Rockville, MD, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS